Compliance with good manufacturing practice (“GMP”) is mandatory for all medicinal products that have been granted a marketing authorisation. Likewise, the manufacture of investigational medicinal products must be in accordance with GMP. Advanced therapy medicinal products that are administered to patients under Article 3 of Directive 2001/83/EC (so called “hospital exemption”) must be manufactured under equivalent quality standards to the manufacturing of advanced therapy medicinal products with a marketing authorisation.
Article 5 of Regulation (EC) No 1394/2007 mandates the Commission to draw up guidelines on good manufacturing practice specific to advanced therapy medicinal products ("ATMPs"). Article 63(1) of Regulation (EU) No 536/2014 also empowers the Commission to adopt and publish detailed guidelines on good manufacturing practice applicable to investigational medicinal products.
EC 22.11.2017
EudraLex 22.11.2017
Acrolein, Crotonaldehyde, and Arecoline
This volume of the IARC Monographs provides evaluations of the carcinogenicity of three chemicals: acrolein, crotonaldehyde, and arecol...
Prodotti fitosanitari contenenti glifosato: divieto del coformulante ammina di sego polietossilata (n. CAS 61791-26-2)
Regolamento di esecuzione (UE) 2016/1313 ...
della Commissione del 7 giugno 2019 che autorizza una misura provvisoria adottata dalla Repubblica francese a norma dell'articolo 129 del regolamento (CE) n. 1907/...
Testata editoriale iscritta al n. 22/2024 del registro periodici della cancelleria del Tribunale di Perugia in data 19.11.2024
